A First-in-human Study of RLY-8161 in Advanced NRAS-Mutant Solid Tumors

Summary

This is a Phase 1 first-in-human, open-label multicenter study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of RLY-8161, an NRAS-selective inhibitor, in participants with advanced NRAS-mutant melanoma and other solid tumors.

Timeline

Start

2026-03-09

Primary completion

2027-12-30

Completion

2029-12-31

Drugs

Indications